Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression

BACKGROUND: No treatment to date is available which specifically targets bone formation in ankylosing spondylitis (AS). Several recent studies have shown that sclerostin (SOST), a Wnt inhibitor specific to osteocytes and chondrocytes, is down-regulated in AS patients. This suggests Wnt signalling ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Haynes, Katelin R., Tseng, Hsu-Wen, Kneissel, Michaela, Glant, Tibor T., Brown, Matthew A., Thomas, Gethin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662039/
https://www.ncbi.nlm.nih.gov/pubmed/26612313
http://dx.doi.org/10.1186/s12891-015-0823-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662039/
https://www.ncbi.nlm.nih.gov/pubmed/26612313
http://dx.doi.org/10.1186/s12891-015-0823-8

Ejemplares similares